መነሻ › የዩቪያል ሜላኖማ › Tennessee
በTennessee ለየዩቪያል ሜላኖማ የሚደረጉ ክሊኒካዊ ጥናቶች
ለየዩቪያል ሜላኖማ የሚደረጉ 6 ጥናቶች በTennessee ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በTennessee ውስጥ ያሉ ከተሞች
Official study text (English)
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
- Sarah Cannon Research Institute (SCRI), Nashville
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ሴፕቴ 2026 · NCT07804186A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
- Sarah Cannon Research Institute, Nashville
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ15 ጁን 2026 · NCT06940739Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ጁን 2026 · NCT03947385Neoadjuvant Darovasertib in Primary Uveal Melanoma
- SCRI Oncology Partners, Nashville
- Vanderbilt Eye Institute, Nashville
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ሜይ 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- The West Clinic, PLLC dba West Cancer Center, Germantown
- University of Tennessee Medical Center, Knoxville
- Sarah Cannon Research Institute, Nashville
- እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኤፕሪ 2026 · NCT06581406Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
- SCRI Oncology Partners, Nashville
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኖቬም 2025 · NCT07136181ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።